Nauru vs Tonga: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Nauru
0.6%
in 2024
Tonga
0.6%
in 2024
Nauru rank
50th
Tonga rank
50th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Nauru
- Tonga
How they compare
Nauru currently reports 0.6% against 0.6% in Tonga, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Nauru ahead.
Nauru ranks 50th and Tonga ranks 50th of 215 countries.
Across the 2 decades both report, Nauru averaged higher in 1 and Tonga in 1.
Head to head by decade
| Decade | Nauru | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.2% | 1.1% | 0.1% | Nauru |
| 2020s | 0.7% | 0.7% | 0.1% | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Nauru or Tonga?
- Nauru, at 0.6% against 0.6% in Tonga as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Nauru and Tonga?
- 0.0%, with Nauru ahead.
- How many years of comparable data are there for Nauru and Tonga?
- 10 years are reported by both, from 2015 to 2024.
- How do Nauru and Tonga rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Nauru ranks 50th and Tonga ranks 50th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.